Medicine & Life Sciences

1. Breast Neoplasms 100%
2. Tamoxifen 40%
3. Neoplasms 37%
4. Melanoma 37%
5. Aromatase Inhibitors 27%
6. Survival 26%
7. Drug Therapy 24%
8. Trastuzumab 23%
9. Therapeutics 22%
10. Recurrence 20%
11. Estrogen Receptors 18%
12. Cytochrome P-450 CYP2D6 17%
13. Progression-Free Survival 17%
14. Letrozole 17%
15. Carboplatin 14%
16. Paclitaxel 14%
17. pazopanib 14%
18. Neoadjuvant Therapy 12%
19. Breast 11%
20. Cyclophosphamide 11%
21. Aromatase 11%
22. Doxorubicin 11%
23. Anastrozole 11%
24. Breast Density 10%
25. Triple Negative Breast Neoplasms 10%
26. Confidence Intervals 10%
27. Disease-Free Survival 10%
28. Radiotherapy 10%
29. 4-hydroxy-N-desmethyltamoxifen 10%
30. Polyurethanes 9%
31. Carcinoma 9%
32. Heterografts 9%
33. Neoplasm Metastasis 8%
34. Multiple Myeloma 8%
35. Adjuvant Chemotherapy 8%
36. Estrogens 7%
37. Biopsy 7%
38. Meta-Analysis 7%
39. Clinical Trials 7%
40. Serum 7%
41. Sentinel Lymph Node 7%
42. 130-nm albumin-bound paclitaxel 7%
43. Lead 7%
44. Mortality 7%
45. Anaplastic Thyroid Carcinoma 7%
46. human ERBB2 protein 7%
47. Tumor Biomarkers 7%
48. Meningioma 6%
49. Endometrial Neoplasms 6%
50. exemestane 6%